Moderna and Merck Report Melanoma Vaccine Results

The companies reported successful phase 3 clinical trial results for a personalized cancer vaccine in August 2026.

Updated on Oct. 24, 2026 in Cancer

Moderna and Merck Report Melanoma Vaccine Results

Live Poll

Is now a good time to invest in companies prioritizing long-term personalized medicine over quarterly profits?

In August 2026, Moderna and Merck announced promising phase 3 clinical trial results for their personalized cancer vaccine, intismeran autogene. The therapy aims to reduce the risk of melanoma recurrence when administered alongside the drug Keytruda.

Why it matters

The vaccine works by training the immune system to identify specific cancer signatures, representing a significant shift in targeted oncology. Its development suggests a new model for preventing cancer relapse in patients following surgical intervention.

The custom vaccine utilizes an algorithm to target 34 specific tumor mutations. Clinical data indicates that 80% of treated patients remained disease-free after five years.

The players

Moderna

This biotechnology company focuses on messenger RNA therapeutics and vaccines for various diseases.

Merck

This multinational pharmaceutical company develops medicines and vaccines for a wide range of global health challenges.

The details

To create the treatment, doctors sequence a patient's tumor and use an algorithm to select 34 mutations for the vaccine. The body then generates specialized T-cells to target the tumor after the patient receives two to three doses.

August 2026: Moderna and Merck reported phase 3 melanoma trial results.
Before year-end 2026: Moderna expects to release pivotal data for propionic acidemia.

The Big Picture

This development extends the success seen in the ongoing clinical development of mRNA-based personalized cancer vaccines. It marks a significant departure from traditional generalized therapies by focusing on highly specific, patient-centered oncological treatments.

Patients may eventually gain access to custom-designed immunotherapies that specifically target their unique tumor profile. This potential shift in standard oncology could offer improved long-term outcomes for those currently struggling with high recurrence rates.

The takeaway

Personalized vaccines represent a significant evolution in how medical science addresses post-surgical cancer prevention. Patients and their families should discuss emerging clinical trial opportunities with their oncologists to stay informed on the latest therapeutic advancements.